AMPH
Amphastar Pharmaceuticals Inc

1,132
Loading...
Loading...
News
all
press releases
CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?
CRMD stock surges nearly 60% YTD as DefenCath drives strong sales, boosted by a $300M Melinta acquisition deal and raised revenue outlook.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?
CRMD's DefenCath, its only revenue source, posts $78.8M in sales in H1 2025, with exclusivity through 2033 fueling growth potential.
Zacks·15d ago
News Placeholder
Is the Options Market Predicting a Spike in Amphastar Pharmaceuticals Stock?
Investors need to pay close attention to AMPH stock based on the movements in the options market lately.
Zacks·15d ago
News Placeholder
Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·1mo ago
News Placeholder
Amphastar (AMPH) Reports Q2 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Amphastar (AMPH) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·1mo ago
News Placeholder
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of +19.72% and +2.69%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
BridgeBio Pharma (BBIO) Reports Q2 Loss, Beats Revenue Estimates
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -14.46% and +14.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know
Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·1mo ago
News Placeholder
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·2mo ago
News Placeholder
Bausch Health (BHC) Lags Q2 Earnings Estimates
Bausch (BHC) delivered earnings and revenue surprises of -7.22% and +2.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago

Latest AMPH News

View

Advertisement. Remove ads.

Advertisement. Remove ads.